The article presents the results of our research on determining the content of Brain-Derived Neurotrophic Factor (BDNF) in the blood serum of healthy individuals and patients with Acute Ischemic Stroke (AIS), depending on the severity of the disease as assessed by the National Institutes of Health Stroke Scale (NIHSS). The neurotrophin content in the blood serum of 30 practically healthy individuals and 85 patients with acute ischemic stroke was studied using an immunoenzymatic method. Using the NIHSS scale, patients were divided into three groups depending on the severity of their neurological symptoms. The group I included 30 patients (10 women and 20 men) with scores ranging from 1 to 5. The group II consisted of 32 patients (6 women and 26 men) with scores ranging from 6 to 13. The group III consisted of 23 patients (11 women and 12 men) with scores ranging from 14 to 20. A statistically significant decrease in the content of brain-derived neurotrophic factor in the blood serum of patients with acute ischemic stroke was observed depending on the severity of the disease. The more severe the stroke, the lower the BDNF content in the patients' blood: compared to healthy persons, the neurotrophin content in patients in group I decreased by 22.6%, and in patients in group II by 39.4%. Patients with the most severe course of acute ischemic stroke experienced the greatest decrease in serum BDNF levels, at 816 %, compared to healthy individuals. According to the study, the brain's neurotrophic factor is an early biochemical marker of trophic dysregulation. This results in impaired growth, survival, and recovery of neurons due to acute ischemic stroke. Keywords: acute ischemic stroke, brain-derived neurotrophic factor, National Institutes of Health Stroke Scale.
P.V. Lebedynets (Mon,) studied this question.